Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)

Clinical trial NCT02978716 · TERMINATED

Trial details

NCT number: NCT02978716
Sponsor: G1 Therapeutics, Inc.
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Triple-Negative Breast Neoplasms Breast Neoplasm Breast Cancer Triple-Negative Breast Cancer

Start date: 2017-02-02
Primary completion: 2019-06-28
Enrollment: 102

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.